Showing results (11-20 of 15,445) with videos related to
Sort By:
Pageof 1,545
Frontiers in Oncology|February 24, 2025
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasmsEsther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, et al.BMJ Open|March 22, 2023
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemiaAli T Taher, Khaled M Musallam, Vip Viprakasit, et al.BMJ Open|November 14, 2024
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trialAli T Taher, Khaled M Musallam, Vip Viprakasit, et al.Hemasphere|May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA TrialRuben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.BMC Cancer|May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE studyStéphane Dalle, Laurent Mortier, Pippa Corrie, et al.Journal of Clinical Medicine|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 TrialEsther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.Journal of Chemical Information and Computer Sciences|November 24, 2004
Active learning with support vector machine applied to gene expression data for cancer classificationYing LiuPageof 1,545